Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 205

The DOI matches its Crossref record.

Long‐term safety of treatment with recombinant human granulocyte colony‐stimulating factor (r‐metHuG‐CSF) in patients with severe congenital neutropenias

Bonilla, Mary Ann, Dale, David, Zeidler, Cornelia, Last, Linda, Reiter, Alfred, Ruggeiro, Mary, Davis, Mark, Koci, Barbara, Hammond, William, Gillio, Alfred, Welte, Karl · 1994 · British Journal of Haematology

Abstract

Summary . Congenital neutropenias include a heterogenous group of diseases characterized by a decrease in circulating neutrophils. In phase I/II/III studies in patients with severe congenital and cyclic neutropenia, treatment with recombinant human granulocyte colony‐stimulating factor (r‐metHuG‐CSF) resulted in a rise in the absolute neutrophil counts (ANC) and a reduction in infections. We report the effects of long‐term safety of subcutaneous r‐metHuG‐CSF administration in 54 patients (congenital n= 44, cyclic n= 10) treated for 4–6 years. A sustained ANC response was seen in 40/44 severe congenital neutropenia patients and 10/10 cyclic neutropenia patients. Two patients required an increase of > 25% in dose to maintain a clinical response; one patient became refractory to therapy. A significant decrease in the incidence of severe infections and the need for intravenous antibiotics was noted. Significant adverse events noted which may or may not be related to therapy included: osteopenia (n= 15), splenomegaly (n= 12), hypersplenism (n= 1), vasculitis (n= 2), glomerulonephritis (n= 1), BM fibrosis (n= 2), MDS/leukaemia (n= 3), and transient inverted chromosome 5q with excess blasts (n= 1). R‐metHuG‐CSF has been well tolerated in the majority of patients and resulted in a longterm improvement in their clinical status.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2141.1994.tb05110.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 205

Metadata

Authors
Bonilla, M. A., Dale, D., Zeidler, C., Last, L., Reiter, A., Ruggeiro, M., Davis, M., Koci, B., Hammond, W., Gillio, A., & Welte, K.
Venue
British Journal of Haematology
Publisher
Wiley
Published
1994-12
Volume
88
Issue
4
Pages
723-730
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W2024016372
Cited by
205
References
0
FWCI
8.78
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long‐term safety of treatment with recombinant human granulocyte colony‐stimulating factor (r‐metHuG‐CSF) in patients with severe congenital neutropenias. https://app.cochat.ai/papers/10.1111/j.1365-2141.1994.tb05110.x
The paper
Bonilla, M. A., Dale, D., Zeidler, C., Last, L., Reiter, A., Ruggeiro, M., Davis, M., Koci, B., Hammond, W., Gillio, A., & Welte, K. (1994). Long‐term safety of treatment with recombinant human granulocyte colony‐stimulating factor (r‐metHuG‐CSF) in patients with severe congenital neutropenias. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.1994.tb05110.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.